FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308045217> ?p ?o ?g. }

• W4308045217 abstract "IntroductionTo analyze outcomes on objective ocular surface parameters and subjective symptoms of serial weekly sessions using the Activa mask in patients with meibomian gland dysfunction (MGD).MethodsThis is a prospective study including patients with symptomatic MGD who were treated with four weekly sessions using the Activa mask (SBM Sistemi, Turin, Italy). Noninvasive ocular surface examination was carried out before (T0) and 2 weeks after the last mask session (T1) using Idra (SBM Sistemi, Turin, Italy) for the measurement of: (1) noninvasive break-up time (NIBUT); (2) lipid layer thickness (LLT); (3) tear meniscus height (TMH); (4) meibomian gland loss (MGL) of upper and lower eyelids. The I-Pen tear osmolarity system (I-Med Pharma Inc, Dollard-des Ormeaux, Quebec, Canada) was used to measure tear osmolarity values. Ocular discomfort symptoms were ascertained by means of the ocular surface disease index (OSDI) questionnaire.ResultsAll 25 patients (11 males, 14 females; mean age 57.1 ± 11.9 years) regularly completed the cycle of four mask sessions. No patients used prohibited medications, and no device-related adverse events were noted. At T1, mean values of NIBUT and LLT increased significantly compared to T0 (respectively from 6.0 ± 1.4 to 6.6 ± 1.2 s, P = 0.043, and from 53.2 ± 17.4 to 65.3 ± 16.3 nm, P < 0.001), while mean values of MGL and tear osmolarity decreased significantly (respectively from 17.1 ± 9.3 to 15.1 ± 8.0%, P = 0.014, and from 307.3 ± 12.2 to 301.5 ± 6.8 mOsm/l, P = 0.005). In parallel, OSDI score reduced significantly from 62.4 ± 11.7 at T0 to 34.5 ± 11.2 at T1 (P < 0.001).ConclusionWeekly serial sessions using the Activa mask significantly improved objective parameters of the ocular surface as well as subjective ocular discomfort symptoms in patients with recalcitrant MGD. As a further benefit from the treatment, patients were able to avoid the use of concomitant medications, apart from tear substitutes, throughout the study." @default.
• W4308045217 created "2022-11-07" @default.
• W4308045217 creator A5009874188 @default.
• W4308045217 creator A5013637628 @default.
• W4308045217 creator A5023549862 @default.
• W4308045217 creator A5058481256 @default.
• W4308045217 creator A5086653980 @default.
• W4308045217 creator A5091885245 @default.
• W4308045217 date "2022-11-03" @default.
• W4308045217 modified "2023-09-30" @default.
• W4308045217 title "Effects of Serial Sessions of Activa Mask for the Treatment of Meibomian Gland Dysfunction" @default.
• W4308045217 cites W2048812754 @default.
• W4308045217 cites W2117679883 @default.
• W4308045217 cites W2163785631 @default.
• W4308045217 cites W2314970472 @default.
• W4308045217 cites W2398899485 @default.
• W4308045217 cites W2531733355 @default.
• W4308045217 cites W2739359388 @default.
• W4308045217 cites W2770322933 @default.
• W4308045217 cites W2781477799 @default.
• W4308045217 cites W2913229857 @default.
• W4308045217 cites W2935665639 @default.
• W4308045217 cites W2971722633 @default.
• W4308045217 cites W2979958141 @default.
• W4308045217 cites W2980582220 @default.
• W4308045217 cites W2989622231 @default.
• W4308045217 cites W3004287203 @default.
• W4308045217 cites W3005972662 @default.
• W4308045217 cites W3088895939 @default.
• W4308045217 cites W3113122840 @default.
• W4308045217 cites W3195463775 @default.
• W4308045217 cites W3213468389 @default.
• W4308045217 cites W4211224529 @default.
• W4308045217 cites W4285797225 @default.
• W4308045217 doi "https://doi.org/10.1007/s40123-022-00604-w" @default.
• W4308045217 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36327001" @default.
• W4308045217 hasPublicationYear "2022" @default.
• W4308045217 type Work @default.
• W4308045217 citedByCount "1" @default.
• W4308045217 countsByYear W43080452172023 @default.
• W4308045217 crossrefType "journal-article" @default.
• W4308045217 hasAuthorship W4308045217A5009874188 @default.
• W4308045217 hasAuthorship W4308045217A5013637628 @default.
• W4308045217 hasAuthorship W4308045217A5023549862 @default.
• W4308045217 hasAuthorship W4308045217A5058481256 @default.
• W4308045217 hasAuthorship W4308045217A5086653980 @default.
• W4308045217 hasAuthorship W4308045217A5091885245 @default.
• W4308045217 hasBestOaLocation W43080452171 @default.
• W4308045217 hasConcept C118487528 @default.
• W4308045217 hasConcept C126322002 @default.
• W4308045217 hasConcept C14705128 @default.
• W4308045217 hasConcept C197934379 @default.
• W4308045217 hasConcept C2777165675 @default.
• W4308045217 hasConcept C2781302119 @default.
• W4308045217 hasConcept C71924100 @default.
• W4308045217 hasConceptScore W4308045217C118487528 @default.
• W4308045217 hasConceptScore W4308045217C126322002 @default.
• W4308045217 hasConceptScore W4308045217C14705128 @default.
• W4308045217 hasConceptScore W4308045217C197934379 @default.
• W4308045217 hasConceptScore W4308045217C2777165675 @default.
• W4308045217 hasConceptScore W4308045217C2781302119 @default.
• W4308045217 hasConceptScore W4308045217C71924100 @default.
• W4308045217 hasLocation W43080452171 @default.
• W4308045217 hasLocation W43080452172 @default.
• W4308045217 hasOpenAccess W4308045217 @default.
• W4308045217 hasPrimaryLocation W43080452171 @default.
• W4308045217 hasRelatedWork W2129071366 @default.
• W4308045217 hasRelatedWork W2317774021 @default.
• W4308045217 hasRelatedWork W2395310626 @default.
• W4308045217 hasRelatedWork W2622079263 @default.
• W4308045217 hasRelatedWork W2801863115 @default.
• W4308045217 hasRelatedWork W2900045077 @default.
• W4308045217 hasRelatedWork W2902476798 @default.
• W4308045217 hasRelatedWork W3031318450 @default.
• W4308045217 hasRelatedWork W3031770295 @default.
• W4308045217 hasRelatedWork W4280514162 @default.
• W4308045217 isParatext "false" @default.
• W4308045217 isRetracted "false" @default.
• W4308045217 workType "article" @default.